The Maternal Opioid Misuse (MOM) Model is providing significant improvements in health outcomes and quality of life for a particularly at-risk communities, according to the latest annual report on the program. In its 2nd year, data note enrollment nearly doubled, although accessibility issues persist.
The MOM Model aims to enhance care for pregnant and postpartum women with Medicaid with opioid use disorder (OUD) and their infants, supported by the CMS Innovation Center in 7 states. Westat developed qualitative, process, and impact evaluation designs to conduct 10 individual model awardee evaluations and a cross-site evaluation.
Clinical best practices for treating OUD in pregnant women have been adopted by model providers, with peer recovery services showing promise. While care delivery partners improved their capacity to treat women, they struggle to find sustainable payment methods for these services. The next evaluation period will focus on assessing the model’s impact on patient outcomes and costs.
“The MOM Model is an example of partnerships between state Medicaid agencies and local maternal health and substance use treatment specialists to transform care for pregnant women with OUD,” notes Westat’s Meg Tucker, MS, MOM Evaluation Project Director. “States with pilot MOM Models are coordinating and integrating care across multiple care disciplines to keep women engaged in treatment while reducing the stigma so many women face in receiving care for their pregnancies while receiving life-saving treatment for OUD.”
Learn More
Focus Areas
Behavioral Health Maternal Health Opioids Public HealthCapabilities
Evaluation and Mixed-Methods ResearchFeatured Expert
Meg Tucker
Principal Research Associate
